"One of the major challenges for scientific research is to have the ability to rapidly screen materials at the nanoscale, and in no field is that more critical than life-saving medical research," said Nanotronics Imaging CEO and founder Dr. Matthew Putman. "Scientists recently discovered, for example, that Alzheimer's disease is not irreversible. Rapid high-resolution imaging of the brain's neurons will be critical to furthering such medical advances, as well as in the study of other debilitating diseases such as schizophrenia. Our high resolution nSPEC® microscope has unparalleled high-area capabilities, covering large areas of the brain, and can reduce imaging time from weeks down to days or even minutes."
Nanotronics Imaging combines a mature technology, the optical microscope, with leading-edge proprietary software, to create fully-automated systems for rapid wide-field inspection of features at the nanometer scale. Nanotronics' technology has been used to create maps of defects and features on semiconductor substrate wafers and to automatically identify and catalog them at a fraction of the cost of any other wafer inspection instrumentation. While the company has achieved significant traction in this market (with applications for LEDs and RF Amplifiers for mobile devices) its patented technology can be applied to many other areas, as evidenced by its welcome foray into the medical field.
About Nanotronics Imaging
Nanotronics Imaging was founded in Akron, Ohio in 2008 by Dr. Matthew Putman and John Putman after selling their previous international instrument business, 25 year old Tech Pro, Inc. to Roper Industries, an S&P 500 company. Nanotronics Imaging's first product, nSPEC®, a semiconductor analysis system, was just released in May of 2011 and is already being sold across three continents. Dr. Matthew Putman, CEO of Nanotronics Imaging, lives in New York, has a PhD in applied physics and is also on the faculty of Columbia University. For more on Nanotronics Imaging go to www.nanotronicsimaging.com .
Posted by Sean Fenske, Editor-in-Chief, MDT